TARE VS TACE:
WHICH LIVER-DIRECTED THERAPY IS RIGHT FOR YOU?
A structured patient-facing comparison of the two most widely used liver-directed therapies โ transarterial radioembolization (TARE/Y-90) and transarterial chemoembolization (TACE) โ across mechanism, eligibility, recovery, and the clinical scenarios where each is the better choice.
analyticsAt a Glance
- check_circleBoth procedures use a catheter in the hepatic artery โ but TARE delivers radiation and TACE delivers chemotherapy + embolization
- check_circleTARE is better tolerated in portal vein thrombosis and in patients who need outpatient-friendly treatment
- check_circleTACE has the larger HCC evidence base and is more widely available globally
- check_circleCancerFax helps patients understand which approach is evidence-supported for their specific case
TARE vs TACE โ Head-to-Head Comparison
A structured comparison across the parameters most relevant to clinical decision-making and patient experience.
| Parameter | TARE (Y-90) | TACE (cTACE or DEB-TACE) |
|---|---|---|
| Active component | Y-90 beta radiation (internal brachytherapy) | Chemotherapy (doxorubicin, cisplatin, mitomycin C) + embolization |
| Embolisation effect | Minimal (esp. TheraSphere glass spheres) | Significant โ deliberately occludes tumour arterial supply |
| Duration of radiation/drug | Continuous radiation for ~11 days (Y-90 decay) | Chemotherapy released over hours to days from lipiodol or DEB |
| Hospital stay | Day case / overnight in most centres | 1โ3 days inpatient typically |
| Post-procedural syndrome | Mild โ fatigue, low-grade fever 24โ72 hrs | Moderate โ pain, fever, nausea (post-embolization syndrome) 3โ7 days |
| Portal vein thrombosis (PVTT) | Safe to use โ minimal embolic load | Contraindicated or high-risk โ additional hepatic artery embolization โ ischaemic risk |
| Bilobar disease treatment | Sequential lobar TARE (2 sessions, ~4โ6 weeks apart) | Sequential lobar TACE (multiple sessions often needed) |
| BCLC stage applicability | A, B, C (selected with PVTT) | A (off-label), B (standard), C only if no main PVTT |
| Evidence base โ HCC | Phase III SARAH, SIRveNIB; extensive retrospective | RCT basis from 1990sโ2000s; BCLC B standard of care |
| Evidence base โ CRLM | Phase III SIRFLOX, FOXFIRE Global | Limited Phase III data; some retrospective evidence |
| Availability | Specialist Y-90 centres with nuclear medicine unit | Most interventional radiology units globally |
| Cost (approximate range) | Higher โ Y-90 supply adds significant cost | Lower โ standard IR consumables and chemotherapy |
When to Choose TARE โ and When to Choose TACE
For many HCC patients, either therapy could be clinically justified. These are the situations where one is clearly preferred over the other.
Choose TARE When:
- Portal vein tumour thrombus is presentTARE's minimal embolic load makes it the locoregional therapy of choice when portal venous flow is compromised โ TACE ischaemia risk is unacceptable in significant PVTT.
- Outpatient treatment is strongly preferredTARE's same-day or overnight profile makes it significantly more convenient than TACE's typical 1โ3 day inpatient admission โ important for patients with logistical, work, or family constraints.
- Radiation segmentectomy is the intentOnly TARE can deliver the ablative doses (>200 Gy) required for radiation segmentectomy of small HCC โ TACE cannot achieve equivalent tumour-specific radiation dosing.
- Radiation lobectomy (FLR augmentation) before surgeryOnly TARE can simultaneously treat tumour and drive lobar atrophy/contralateral hypertrophy for surgical preparation.
- TACE failure or repeated TACE intolerancePatients who have progressed on or cannot tolerate TACE are the primary TARE referral population โ the mechanism is entirely different so prior TACE failure does not predict TARE failure.
Choose TACE When:
- Standard BCLC B first-line treatment (guideline-supported)TACE has decades of RCT evidence and BCLC guideline endorsement for intermediate HCC โ the default standard of care for new BCLC B diagnoses at most centres globally.
- Access constraints โ TARE not locally availableTACE requires only standard IR equipment; TARE requires a Y-90 supply chain and nuclear medicine infrastructure unavailable at most hospitals globally.
- HCC with preserved hepatic artery patency and no PVTTWhen hepatic artery anatomy is straightforward and portal flow is intact, TACE's additional chemotherapy component adds tumour kill that TARE's radiation alone may not.
- Cost-constrained healthcare settingsTACE is substantially cheaper than TARE โ an important consideration in resource-limited settings or without insurance coverage for Y-90.
- When large volume embolization is therapeutically desiredFor very large, hypervascular HCC lesions, the deliberate embolic devascularisation component of TACE adds significant cytoreductive benefit alongside chemotherapy.
TARE vs TACE โ Clinical Outcomes Comparison
Comparative outcome data from the most relevant head-to-head trials and meta-analyses in HCC.
TARE vs TACE in Intermediate HCC โ Meta-Analysis (OS)
Pooled OS data from comparative studies and meta-analyses of TARE vs TACE in intermediate-stage HCC. Source: Spreafico et al., multiple meta-analyses 2017โ2022.
- Median OS: TARE (intermediate HCC)~20โ26 months
- Median OS: TACE (intermediate HCC)~17โ22 months
Post-Procedural Toxicity โ Grade 3+ Adverse Events
Grade 3โ4 adverse events from the SARAH Phase III trial comparing TheraSphere vs sorafenib โ with TACE toxicity from contemporaneous BCLC B TACE series for context.
- Grade 3โ4 AEs: TARE (SARAH trial)28%
- Grade 3โ4 AEs: TACE (typical range)~35โ45%
TARE vs TACE โ Key Comparison Numbers
The most clinically relevant quantitative differences between the two therapies.
- Day case vs 1โ3 daysHospital stay: TARE vs TACETARE's outpatient profile is one of its most patient-meaningful advantages โ enabling treatment without the disruption of a multi-day inpatient admission.
- Contraindicated vs SafeTACE vs TARE in portal vein tumour thrombusThe most clinically critical difference โ TACE carries ischaemia risk in PVTT while TARE's minimal embolic load preserves residual hepatic perfusion.
- โฅ200 Gy vs ~0 GyAchievable tumour radiation dose: TARE vs TACETARE can deliver ablative radiation doses; TACE delivers no meaningful ionising radiation dose โ the therapeutic mechanisms are entirely non-overlapping.
More from the TARE / Y-90 Resource Library
Continue exploring TARE โ from the HCC evidence base and radiation segmentectomy to treatment day and post-procedure safety.
Frequently Asked Questions: TARE vs TACE
Can TARE and TACE be combined or used sequentially for the same patient?
Yes โ sequential and combined use is practised at specialist centres. Common approaches include: TACE for initial cytoreduction followed by TARE for radiation consolidation of residual disease; TARE after TACE failure or intolerance; and in some protocols, TACE to the contralateral lobe alongside TARE of the dominant tumour lobe. Sequential use does not preclude either therapy as long as liver function and arterial anatomy remain adequate for each subsequent procedure. CancerFax identifies centres in China and India experienced in both modalities and sequential approaches.
My tumour responded partially to TACE but has now grown again. Should I switch to TARE?
TACE failure or incomplete response is one of the most common indications for TARE referral. Because TARE operates via a completely different mechanism (radiation vs chemotherapy + embolization), prior TACE response or failure does not predict TARE response โ patients who progressed on TACE can achieve meaningful tumour control and survival benefit with TARE. The key assessments before switching are: adequate remaining liver function (Child-Pugh A or early B), patent hepatic arterial anatomy (multiple TACE sessions can cause arterial damage or occlusion), acceptable lung shunt fraction at mapping, and confirmed absence of extrahepatic disease that would preclude benefit from liver-directed therapy.
Is TARE better than TACE for HCC?
Neither is definitively 'better' โ each is better suited to specific clinical situations. TARE has advantages in portal vein thrombosis, outpatient convenience, radiation segmentectomy, and TACE-refractory patients. TACE has the longer guideline-supported evidence base for intermediate HCC, wider global availability, and lower cost. The right choice depends on your specific BCLC stage, portal vein status, liver function, treatment intent, and the expertise available at the treating centre. CancerFax's case review process identifies which approach is more evidence-supported for your specific situation.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Not Sure Whether TARE or TACE Is Right for Your Liver Cancer?
CancerFax reviews your liver tumour records โ BCLC stage, portal vein status, Child-Pugh score, and prior treatment โ and connects you with specialist interventional oncology centres in China and India for an expert recommendation.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist and interventional radiologist before making treatment decisions.